Head and Neck Cancers
OS: Low dose Nivolumab + Metronomic chemotherapy
In a randomized phase III Indian study, the addition of low dose nivolumab to chemotherapy improved overall survival in patients...
"AHOD1331 study - Bv-AVEPC approved for 2-year-olds and older with previously untreated high risk cHL "
On November 10, 2022, the FDA approved #brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric...
Adjuvant capecitabine in locoregionally advanced NPC (LA-NPC)
In a Chinese trial published in JAMA oncology, the addition of adjuvant #capecitabine improved failure-free survival (FFS) among patients with...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
.png)